LFLY vs. CCLD, VCNX, CANF, TRVN, AQB, KTTA, XWEL, PSTV, HEPA, and ADXS
Should you be buying Leafly stock or one of its competitors? The main competitors of Leafly include CareCloud (CCLD), Vaccinex (VCNX), Can-Fite BioPharma (CANF), Trevena (TRVN), AquaBounty Technologies (AQB), Pasithea Therapeutics (KTTA), XWELL (XWEL), Plus Therapeutics (PSTV), Hepion Pharmaceuticals (HEPA), and Ayala Pharmaceuticals (ADXS). These companies are all part of the "medical" sector.
CareCloud (NASDAQ:CCLD) and Leafly (NASDAQ:LFLY) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, profitability and community ranking.
CareCloud received 2 more outperform votes than Leafly when rated by MarketBeat users. Likewise, 62.50% of users gave CareCloud an outperform vote while only 37.50% of users gave Leafly an outperform vote.
In the previous week, Leafly had 3 more articles in the media than CareCloud. MarketBeat recorded 3 mentions for Leafly and 0 mentions for CareCloud. CareCloud's average media sentiment score of 0.50 beat Leafly's score of 0.00 indicating that Leafly is being referred to more favorably in the news media.
Leafly has a net margin of -22.48% compared to Leafly's net margin of -41.58%. CareCloud's return on equity of 0.00% beat Leafly's return on equity.
10.2% of CareCloud shares are held by institutional investors. Comparatively, 15.6% of Leafly shares are held by institutional investors. 36.9% of CareCloud shares are held by insiders. Comparatively, 11.3% of Leafly shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Leafly has lower revenue, but higher earnings than CareCloud. Leafly is trading at a lower price-to-earnings ratio than CareCloud, indicating that it is currently the more affordable of the two stocks.
CareCloud has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Leafly has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.
CareCloud currently has a consensus price target of $3.17, suggesting a potential upside of 198.74%. Leafly has a consensus price target of $6.00, suggesting a potential upside of 104.78%. Given Leafly's higher probable upside, research analysts plainly believe CareCloud is more favorable than Leafly.
Summary
CareCloud beats Leafly on 9 of the 17 factors compared between the two stocks.
Get Leafly News Delivered to You Automatically
Sign up to receive the latest news and ratings for LFLY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LFLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
